Insider Buying: Enovis (NYSE:ENOV) Insider Purchases 1,000 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 1,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was bought at an average price of $20.92 per share, for a total transaction of $20,920.00. Following the purchase, the insider owned 53,640 shares in the company, valued at approximately $1,122,148.80. This trade represents a 1.90% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Thursday, June 11th, Oliver Engert purchased 1,200 shares of Enovis stock. The shares were acquired at an average price of $21.62 per share, for a total transaction of $25,944.00.
• On Wednesday, June 10th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were acquired at an average price of $23.00 per share, for a total transaction of $23,000.00.
• On Monday, June 1st, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were acquired at an average price of $22.22 per share, for a total transaction of $22,220.00.

Enovis Stock Performance

Shares of NYSE ENOV traded up $0.58 during trading hours on Tuesday, hitting $21.56. 1,076,256 shares of the stock were exchanged, compared to its average volume of 1,004,754. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The company’s 50 day moving average is $23.97 and its 200 day moving average is $24.44. The firm has a market capitalization of $1.24 billion, a P/E ratio of -1.08 and a beta of 1.38. Enovis Corporation has a one year low of $20.55 and a one year high of $36.82.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same period in the prior year, the firm earned $0.81 EPS. Enovis’s quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts expect that Enovis Corporation will post 3.65 EPS for the current year.

Institutional Investors Weigh In On Enovis

Several institutional investors have recently modified their holdings of ENOV. Rubric Capital Management LP acquired a new stake in shares of Enovis during the 3rd quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY boosted its stake in Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after acquiring an additional 732,917 shares during the last quarter. AQR Capital Management LLC boosted its stake in Enovis by 682.6% during the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after acquiring an additional 434,646 shares during the last quarter. Front Street Capital Management Inc. boosted its stake in Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after acquiring an additional 384,124 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its stake in Enovis by 130.8% during the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after acquiring an additional 342,556 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $39.00 price objective on shares of Enovis in a report on Friday, May 22nd. William Blair assumed coverage on shares of Enovis in a report on Friday, April 17th. They set an “outperform” rating for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Zacks Research downgraded shares of Enovis from a “strong-buy” rating to a “hold” rating in a report on Monday, June 1st. Finally, Evercore reissued an “outperform” rating and set a $36.00 price target on shares of Enovis in a report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.50.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.